Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.

Clinical pharmacology and therapeutics - 1 Mar 2004

Kamali Farhad, Khan Tayyaba Irfan, King Barry P, Frearson Richard, Kesteven Patrick, Wood Peter, Daly Ann K, Wynne Hilary

Abstract excerpt

OBJECTIVE: Our objective was to assess the contribution of CYP2C9 genotype, age, body size, and vitamin K and lipid status to warfarin dose requirements. METHODS: Patients with stable warfarin dose requirements and an international normalized ratio (INR) of the prothrombin time within the target range of 2.0 to 3.0 were recruited to the study. On arrival at the clinic in the morning, after an overnight fast, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aging
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Body Constitution

Share to Cytochrome P-450 CYP2C9

Share to Metabolic Clearance Rate

Share to Predictive Value of Tests

Share to Warfarin

Source

Identifiers

PMID: 15001972
DOI: 10.1016/j.clpt.2003.10.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.PMID 15001972Read ↗

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.Semantic proximity Read ↗

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.Semantic proximity Read ↗

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.Semantic proximity Read ↗

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.Semantic proximity Read ↗

[Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].Semantic proximity Read ↗

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Semantic proximity Read ↗

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.Semantic proximity Read ↗

The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.Semantic proximity Read ↗

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.Semantic proximity Read ↗

Interindividual variability in sensitivity to warfarin--Nature or nurture?Semantic proximity Read ↗

Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.Semantic proximity Read ↗

Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.